Akari Therapeutics Plc (AKTX)
8.225
+0.12
(+1.54%)
USD |
NASDAQ |
Oct 23, 16:00
8.235
+0.01
(+0.12%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value : 7.336M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 7.336M |
| October 22, 2026 | 7.117M |
| October 21, 2026 | 8.272M |
| October 20, 2026 | 9.200M |
| October 19, 2026 | 10.25M |
| October 16, 2026 | 7.257M |
| October 15, 2026 | 8.412M |
| October 14, 2026 | 5.682M |
| October 13, 2026 | 6.767M |
| October 12, 2026 | 7.887M |
| October 09, 2026 | 8.29M |
| October 08, 2026 | 7.170M |
| October 07, 2026 | 8.036M |
| October 06, 2026 | 7.625M |
| October 05, 2026 | 8.588M |
| October 02, 2026 | 8.202M |
| October 01, 2026 | 8.412M |
| September 30, 2026 | 9.218M |
| September 29, 2026 | 9.953M |
| September 28, 2026 | 10.11M |
| September 25, 2026 | 10.01M |
| September 24, 2026 | 10.55M |
| September 23, 2026 | 9.848M |
| September 22, 2026 | 10.53M |
| September 21, 2026 | 9.358M |
| Date | Value |
|---|---|
| September 18, 2026 | 8.973M |
| September 17, 2026 | 10.22M |
| September 16, 2026 | 10.65M |
| September 15, 2026 | 10.88M |
| September 14, 2026 | 12.26M |
| September 11, 2026 | 12.72M |
| September 10, 2026 | 11.98M |
| September 09, 2026 | 11.44M |
| September 08, 2026 | 12.12M |
| September 04, 2026 | 13.02M |
| September 03, 2026 | 11.91M |
| September 02, 2026 | 10.71M |
| September 01, 2026 | 11.09M |
| August 31, 2026 | 11.20M |
| August 28, 2026 | 11.67M |
| August 27, 2026 | 8.710M |
| August 26, 2026 | 8.868M |
| August 25, 2026 | 6.715M |
| August 24, 2026 | 6.014M |
| August 21, 2026 | 6.680M |
| August 20, 2026 | 6.575M |
| August 19, 2026 | 6.767M |
| August 18, 2026 | 6.765M |
| August 17, 2026 | 6.102M |
| August 14, 2026 | 6.137M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 364.13M |
| Cellectis SA | 36.12M |
| Bicycle Therapeutics Plc | -316.00M |
| argenx SE | 54.00B |
| Autolus Therapeutics Plc | 574.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.816M |
| Total Expenses (Quarterly) | 4.816M |
| EPS Diluted (Quarterly) | -2.404 |
| Earnings Yield | -240.4% |